CMPS - Compass Pathways Plc - ADR
IEX Last Trade
7.48
-0.160 -2.139%
Share volume: 467,685
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$7.64
-0.16
-2.09%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.03%
1 Month
-1.71%
3 Months
0.81%
6 Months
-39.53%
1 Year
-18.43%
2 Year
-52.05%
Key data
Stock price
$7.48
DAY RANGE
N/A - N/A
52 WEEK RANGE
$5.01 - $12.75
52 WEEK CHANGE
-$0.20
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO:
Region: US
Website: https://compasspathways.com/
Employees: 186
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://compasspathways.com/
Employees: 186
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
Recent news